TheraRadar
← Back
Data updated: Jun 28, 2026

Novartis

NVS Big Pharma
OncologyCardiovascularOphthalmology Execution: Excellent

Swiss pharma focused on innovative medicines and generics (Sandoz). Leading positions in oncology, ophthalmology, and cardiovascular. Major drugs include Entresto, Cosentyx, and Kisqali.

$50.3B
Revenue (2024)
$210.0B
Market Cap
-
Trials
12
New Drugs (2yr)
Modality:
91 Small Molecules 7 Biologics

FDA Novel Drug Designations

(2017-2025)
16 Novel 8 First-in-Class 7 Orphan 7 Breakthrough 3 Accelerated 9 Priority Review 3 Fast Track
See 16 novel approvals →
2025 TRYPTYR (ACOLTREMON) First-in-Class
2025 RHAPSIDO (REMIBRUTINIB) First-in-Class
2025 VANRAFIA (ATRASENTAN HYDROCHLORIDE) Accelerated
2023 FABHALTA (IPTACOPAN HYDROCHLORIDE) First-in-Class · Orphan · Breakthrough
2022 PLUVICTO (LUTETIUM LU-177 VIPIVOTIDE TETRAXETAN) First-in-Class · Orphan · Breakthrough · Priority Review
2021 LEQVIO (INCLISIRAN SODIUM) First-in-Class · Priority Review
2021 SCEMBLIX (ASCIMINIB HYDROCHLORIDE) Orphan · Breakthrough · Priority Review · Accelerated · Fast Track
2020 TABRECTA (CAPMATINIB HYDROCHLORIDE) Orphan · Breakthrough · Priority Review · Accelerated
2019 PIQRAY (ALPELISIB) Priority Review
2019 ADAKVEO (CRIZANLIZUMAB-TMCA) First-in-Class · Orphan · Breakthrough · Priority Review
2019 EGATEN (TRICLABENDAZOLE) Orphan · Priority Review · Fast Track
2019 BEOVU (brolucizumab-dbll)
2019 MAYZENT (SIPONIMOD)
2017 KISQALI (RIBOCICLIB SUCCINATE) Breakthrough · Priority Review
2017 RHOPRESSA (NETARSUDIL MESYLATE) First-in-Class
2017 RYDAPT (MIDOSTAURIN) First-in-Class · Orphan · Breakthrough · Priority Review · Fast Track

Novartis at a Glance

  • Strong track record with 95% execution quality across 175 trials
  • Fast trial execution (11 months median completion)

Novartis's Recent FDA Approvals

Novartis secured 12 new FDA approvals for novel drugs (NDA/BLA) in the last two years.

APREPITANT NDA
2026-06-16
aprepitant
Nausea
DULOXETINE HYDROCHLORIDE NDA
2026-02-27
duloxetine hydrochloride
ITVISMA BLA
2025-11-23
onasemnogene abeparvovec-brve
1 INDICATIONS AND USAGE ITVISMA is indicated for the treatment of spinal muscular atrophy (SMA) in adult and pediatric patients 2 years of age and older with confirmed mutation in survival motor neuron 1 (SMN1) gene. ITVISMA is an adeno-associated virus (AAV) vector-based gene therapy indicated for the treatment of spinal muscular atrophy (SMA) in adult and pediatric patients 2 years of age and older with confirmed mutation in SMN1 gene. ( 1 )
ROCURONIUM BROMIDE NDA
2025-10-24
rocuronium bromide
Routine tracheal intubation
RHAPSIDO NDA
2025-09-30
remibrutinib
Chronic Spontaneous Urticaria
LOPRESSOR NDA
2025-08-28
metoprolol tartrate
Hypertension
FAMOTIDINE NDA
2025-07-16
famotidine
1 INDICATIONS AND USAGE Famotidine tablets are indicated in adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer (GU). • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. Famotidine tablets are indicated in adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of duodenal ulcer recurrence. Famotidine tablets are a histamine-2 (H 2 ) receptor antagonist indicated ( 1 ): In adult and pediatric patients 40 kg and greater for the treatment of: • active duodenal ulcer (DU). • active gastric ulcer. • symptomatic nonerosive gastroesophageal reflux disease (GERD). • erosive esophagitis due to GERD, diagnosed by biopsy. In adults for the: • treatment of pathological hypersecretory conditions (e.g., Zollinger-Ellison syndrome, multiple endocrine neoplasias). • reduction of the risk of DU recurrence.
ROCURONIUM BROMIDE NDA
2025-06-09
rocuronium bromide
Routine tracheal intubation
TRYPTYR NDA
2025-05-28
acoltremon
Dry Eye Disease
LOPRESSOR NDA
2025-04-10
metoprolol tartrate
Hypertension

Novartis's Therapeutic Areas

Novartis's approved drugs and pipeline span 5 therapeutic areas, led by Oncology and Cardiovascular, across 7 biologic and 91 small-molecule drugs. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Oncology 33%
36 drugs Phase 3: 95 Phase 2: 177 Phase 1: 281
Cardiovascular 21%
39 drugs Phase 3: 83 Phase 2: 62 Phase 1: 89
Ophthalmology 16%
20 drugs Phase 3: 77 Phase 2: 40 Phase 1: 89
Respiratory 15%
8 drugs Phase 3: 86 Phase 2: 62 Phase 1: 48
Immunology 14%
13 drugs Phase 3: 82 Phase 2: 39 Phase 1: 28

Novartis's Top Competitors

Novartis's closest competitors by therapeutic-area and drug-target overlap include Bayer, AstraZeneca, and Boehringer Ingelheim. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Bayer big-pharma
Oncology, Cardiovascular, Respiratory, Ophthalmology
AstraZeneca big-pharma
Oncology, Respiratory, Cardiovascular, Immunology
Boehringer Ingelheim big-pharma
Respiratory, Oncology, Cardiovascular, Immunology
Merck big-pharma
Oncology, Cardiovascular, Respiratory
AbbVie big-pharma
Immunology, Oncology, Ophthalmology

Novartis Pipeline Snapshot

Novartis has 1338 active clinical programs from ClinicalTrials.gov — 423 Phase 3, 380 Phase 2 and 535 Phase 1.

423
Phase 3
380
Phase 2
535
Phase 1

Phase 3 Readout Calendar Pro

8 Phase 3 trials with confidence-graded primary completion dates.

Full calendar →
Q3 2026
JDQ443
Non-Small Cell Lung Cancer
Estimated · fresh NCT05132075
Q4 2026
CYB704
Relapsing Multiple Sclerosis
Estimated · fresh NCT06847724
Q4 2026
Inclisiran sodium 300 mg
Coronary Artery Disease
Estimated · fresh NCT05360446
Unlock 5 more readouts with confidence-graded estimates
Upgrade to Pro

Anchored on CT.gov primary completion date. Topline announcements typically precede this by 3–9 months. Confidence labels combine date type (ACTUAL/ESTIMATED) with last-update freshness.

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • COSENTYX leads revenue
  • • 5 key drugs tracked
View revenue breakdown →

Trial Catalysts

  • • Oncology pipeline focus
  • • 8 Phase 3 readouts tracked
View readout calendar →

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis
View patent timeline →

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison
Compare with competitor →

Execution Intelligence

  • • Phase 3: 65/67 completed
  • • Speed: 11 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges